Head-to-head · WeighScore
Aquivia Health vs RxSpan MD
The verdict
RxSpan MD takes it — 86.8/100 to 72.2/100.
RxSpan MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A physician-led telehealth under board-certified founder Dr. John Diaz with a broad GLP-1 menu — compounded semaglutide and tirzepatide by injection or oral capsule, plus a brand-name lane and microdosing — on transparent all-inclusive pricing to all 50 states.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Aquivia Health | RxSpan MD |
|---|---|---|
| WeighScore | 72.2/100 | 86.8/100 |
| Grade | C | B |
| Scorecard rank | #81 | #4 |
| Semaglutide | $149/mo | From $194/mo |
| Tirzepatide | $179/mo | $329/mo |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #81 · C
Strengths
- Clinical care provided by Open Loop Healthcare Partners, PC — a reused, verified MSO network
- Named leadership: Steven Bishop MD (CMO), Phillip Gray PharmD (Chief Pharmacist), Tom Foster (President)
- Itemized public pricing: compounded semaglutide $149/mo, tirzepatide $179/mo, Ozempic $1,299, Zepbound $1,399
- Both compounded and branded GLP-1s offered side by side — unusual for a compounded provider
- Self-pay model with no insurance required and no separate consultation fee
Where it loses points
- No public list of states served — you must complete intake to learn if your state qualifies
- No named 503A compounding pharmacy partner, limiting licensure verification
- No LegitScript, PCAB, or BBB trust badges visible
- Brand confusion: site schema names 'CatalystMD' while the customer-facing brand is Aquivia Health
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #4 · B
Strengths
- Available in all 50 states
- Transparent, all-inclusive published pricing — consult, medication, supplies, shipping and support, cancel anytime, from ~$194/mo compounded semaglutide on an annual plan
- Both injectable and a real oral (capsule) route, plus compounded and an advertised brand-name lane
- Physician-led by a named, board-certified founder (Dr. John Diaz) with 24/7 messaging and coaching
Where it loses points
- Compounded semaglutide/tirzepatide are not FDA-approved (not the same as Wegovy/Ozempic/Zepbound)
- Published pricing is for the compounded line — brand-name pricing isn’t itemized
- A prescription isn’t guaranteed — a provider reviews eligibility after checkout
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.